certainativ

Certainativ is a medication used for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects the nerve cells responsible for controlling voluntary muscle movement. The medication is administered via a nasal spray and contains the active ingredients homoharringtonine and busulphan.

Certainativ was approved for medical use in the United States by the Food and Drug Administration in May 2022, following a priority review. It is the first treatment to be approved for the slowing of disease progression in ALS, with the potential to delay symptom worsening. Clinical trials have demonstrated that the medication slows down disease progression compared to being on a placebo.

Research on the efficacy and safety of Certainativ for ALS treatment involved patients with an expanded non-ambulatory ALS diagnosis. These individuals generally have an advanced disease status, with limited ability to engage in daily activities. The treatment was found to slow down clinical deterioration but did not provide instant, noticeable improvement.

The side effects associated with Certainativ use can include certain ones from its two main compounds: homoharringtonine and busulphan. These may include, but are not limited to: neutropenia, thrombocytopenia, a greater chance of experiencing bruising or bleeding, gastrointestinal side effects, increased risk of infections, and constitutional symptoms. Direct prescribers should promptly address side effects and ensure clear, detailed guidelines under the U.S. Food and Drug Administration (FDA).

Certainativ is the first systemic drug approved in the United States for using an anti-proliferative prescription in the nervous system. The drug extends life expectancy for ALS patients by promoting greater range of motion and preventing nerve toxicity.